Riesgo de síndrome de lisis tumoral aguda                                   Risk of acute tumor lysis syndrome 

Mackiewicz T. Prevention of tumor lysis syndrome in an outpatient setting. Clin J Oncol Nurs. 2012; 16(2):189-93.

Maloney K, Denno M. Tumor lysis syndrome: prevention and detection to enhance  patient safety. Clin J Oncol Nurs. 2011; 15(6):601-3.

Walker DK, Held-Warmkessel J. Acute promyelocytic leukemia: an overview with implications for oncology nurses. Clin J Oncol Nurs. 2010; 14(6):747-59.

Miller KC, Musial L, Whitworth A, Chanan-Khan A. Management of patients with chronic lymphocytic leukemia treated with lenalidomide. Clin J Oncol Nurs. 2010;14(4):491-9.

Pitello N, Treon M, Jones KL, Kiel PJ. Approaches for administering chemotherapy in the intensive care unit. Curr Drug Saf. 2010; 5(1):22-32.

King JE. What is tumor lysis syndrome? Nursing. 2008; 38(5):18.

Haut C. Oncological emergencies in the pediatric intensive care unit. AACN Clin Issues. 2005; 16(2):232-45.

Jeha S, Pui CH. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. Contrib Nephrol. 2005;147:69-79.

Leon TG, Pase M. Essential oncology facts for the float nurse. Medsurg Nurs. 2004 Jun;13(3):165-89.

Kaplow R. Pathophysiology, signs, and symptoms of acute tumor lysis syndrome. Semin Oncol Nurs. 2002; 18(3 Suppl 3):6-11.

Doane L. Overview of tumor lysis syndrome. Semin Oncol Nurs. 2002; 18(3 Suppl 3):2-5.

Truini-Pittman L, Rossetto C. Pediatric considerations in tumor lysis syndrome. Semin Oncol Nurs. 2002; 18(3 Suppl 3):17-22.

Gobel BH. Management of tumor lysis syndrome: prevention and treatment. Semin Oncol Nurs. 2002; 18(3 Suppl 3):12-6.

Tan SJ. Recognition and treatment of oncologic emergencies. J Infus Nurs. 2002; 25(3):182-8.

Brant JM. Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome. Clin J Oncol Nurs. 2002; 6(1):12-6. 

Versión para imprimir Versión para imprimir | Mapa del sitio